GALT Galectin Therapeutics Inc. Stock Quote

GALT [NASD]

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	14.30%	Shs Outstand	59.35M	Perf Week	-1.54%
Market Cap	74.83M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	0.01%	Shs Float	36.36M	Perf Month	-24.71%
Income	-30.70M	PEG	-	EPS next Q	-0.14	Inst Own	12.60%	Short Float	6.61%	Perf Quarter	-39.91%
Sales	-	P/S	-	EPS this Y	-26.70%	Inst Trans	0.57%	Short Ratio	21.04	Perf Half Y	-54.77%
Book/sh	0.01	P/B	128.00	EPS next Y	-28.80%	ROA	-90.20%	Target Price	14.00	Perf Year	-69.52%
Cash/sh	0.68	P/C	1.89	EPS next 5Y	-	ROE	-321.30%	52W Range	1.26 - 4.57	Perf YTD	-38.16%
Dividend	-	P/FCF	-	EPS past 5Y	7.30%	ROI	-	52W High	-71.99%	Beta	1.66
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	-	Gross Margin	-	52W Low	1.59%	ATR	0.11
Employees	9	Current Ratio	4.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	34.68	Volatility	8.41% 7.51%
Optionable	Yes	Debt/Eq	72.50	EPS Q/Q	11.50%	Profit Margin	-	Rel Volume	0.57	Prev Close	1.35
Shortable	Yes	LT Debt/Eq	72.50	Earnings	-	Payout	-	Avg Volume	114.16K	Price	1.28
Recom	2.00	SMA20	-14.47%	SMA50	-21.05%	SMA200	-49.43%	Volume	64,835	Change	-5.19%

Aug-13-20

Reiterated

H.C. Wainwright

Buy

$9 → $12

Feb-13-19

Initiated

B. Riley FBR

Buy

$11

Dec-07-17

Reiterated

H.C. Wainwright

Buy

$6 → $10

Nov-28-17

Reiterated

H.C. Wainwright

Buy

$3.50 → $6

Oct-19-17

Initiated

ROTH Capital

Buy

Mar-30-17

Upgrade

H.C. Wainwright

Neutral → Buy

$3.50

Oct-03-16

Downgrade

FBR & Co.

Outperform → Mkt Perform

$12 → $2

Sep-29-16

Downgrade

H.C. Wainwright

Buy → Neutral

$1.50

Sep-28-16

Downgrade

ROTH Capital

Buy → Sell

Mar-28-16

Resumed

H.C. Wainwright

Buy

Sep-21-15

Initiated

H.C. Wainwright

Buy

Aug-01-14

Downgrade

Aegis Capital

Buy → Hold

Jul-30-14

Reiterated

MLV & Co

Buy

$27 → $16

Jul-29-14

Reiterated

MLV & Co

Buy

$27 → $15

Apr-02-14

Reiterated

MLV & Co

Buy

$20 → $27

Feb-10-14

Reiterated

Aegis Capital

Buy

$16 → $32

Jan-09-14

Reiterated

Aegis Capital

Buy

$10 → $16

Dec-03-13

Initiated

MLV & Co

Buy

$20

Aug-19-13

Reiterated

Aegis Capital

Buy

$7 → $10

May-16-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update GlobeNewswire -7.35%
May-11-22 11:20AM	Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y Zacks -6.47%
May-03-22 08:30AM	Nano Dimensions Preliminary Q1/2022 Revenues: Approximately $10.5 Million GlobeNewswire
Apr-15-22 07:20AM	Is Galectin Therapeutics Inc. (NASDAQ:GALT) Popular Amongst Insiders? Simply Wall St.
Apr-14-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis GlobeNewswire +10.13%
Mar-31-22 08:00AM	Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update GlobeNewswire -5.85%
Jan-06-22 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference GlobeNewswire
Dec-21-21 08:00AM	Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein GlobeNewswire
Dec-13-21 08:00AM	Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting GlobeNewswire
Nov-15-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update GlobeNewswire
Nov-05-21 04:24PM	UPDATE Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD GlobeNewswire
Oct-27-21 08:00AM	Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD GlobeNewswire
Oct-05-21 03:39PM	UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 GlobeNewswire
01:55PM	Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-21-21 08:00AM	Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein GlobeNewswire
Sep-09-21 09:00AM	Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-30-21 08:00AM	Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis GlobeNewswire
Aug-16-21 09:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update GlobeNewswire
Jul-30-21 04:28AM	Here's What Galectin Therapeutics Inc.'s (NASDAQ:GALT) Shareholder Ownership Structure Looks Like Simply Wall St.
Jul-09-21 09:25AM	Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer Benzinga +25.00%
08:00AM	Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer GlobeNewswire
06:29AM	Galectin Therapeutics Soars on Positive Melanoma Treatment Data TheStreet.com
Jun-13-21 11:23PM	Is Galectin Therapeutics Inc. (GALT) A Good Stock To Buy? Insider Monkey
May-17-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update GlobeNewswire
Apr-27-21 09:28AM	Galectin Therapeutics to Present at 4th Global NASH Congress GlobeNewswire
Apr-19-21 08:00AM	World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Companys Galectin-3 Inhibitor, Belapectin GlobeNewswire +26.94%
Apr-15-21 09:00AM	Company News for Apr 15, 2021 Zacks -5.51%
Apr-14-21 08:28AM	Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response Benzinga +9.01%
Apr-13-21 07:01PM	Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy GlobeNewswire
Apr-06-21 08:00AM	Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study GlobeNewswire +35.27%
Mar-31-21 08:00AM	Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update GlobeNewswire +6.90%
Mar-08-21 08:00AM	OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy GlobeNewswire
Mar-04-21 08:00AM	Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference GlobeNewswire -6.44%
Jan-31-21 02:28AM	What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)? Simply Wall St.
Jan-19-21 11:15AM	Insider Sells Galectin Therapeutics Stock Benzinga
Dec-11-20 08:00AM	Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020 GlobeNewswire
Dec-04-20 04:17PM	Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation GlobeNewswire
Dec-01-20 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders GlobeNewswire
Nov-09-20 08:00AM	Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020 GlobeNewswire
Nov-02-20 08:02AM	Galectin Therapeutics (NASDAQ:GALT) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Oct-12-20 08:11AM	New Strong Sell Stocks for October 12th Zacks
Oct-06-20 03:30PM	These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright TipRanks
Sep-29-20 12:00PM	Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today GlobeNewswire -9.34%
08:52AM	Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options Zacks
Sep-22-20 08:04AM	Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 GlobeNewswire
Sep-10-20 08:00AM	Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 GlobeNewswire
Sep-09-20 11:46AM	Insider Buys Galectin Therapeutics Stock Benzinga +6.79%
Sep-02-20 08:00AM	Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer GlobeNewswire
Aug-10-20 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update GlobeNewswire
Aug-03-20 12:48PM	Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Jun-30-20 09:05AM	UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis GlobeNewswire
08:00AM	Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis GlobeNewswire
Jun-04-20 09:48PM	Hedge Funds Are Souring On Galectin Therapeutics Inc. (GALT) Insider Monkey
May-22-20 08:17AM	Galectin Therapeutics' Shares March Higher, Can It Continue? Zacks +8.25%
May-11-20 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update GlobeNewswire
May-04-20 08:37AM	Companies Like Galectin Therapeutics (NASDAQ:GALT) Are In A Position To Invest In Growth Simply Wall St. +8.52%
Apr-30-20 09:00AM	Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis GlobeNewswire -8.97%
Apr-02-20 08:04AM	Galectin Therapeutics Update on the Impact of COVID-19 GlobeNewswire -7.26%
Mar-16-20 08:00AM	Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update GlobeNewswire -17.41%
Feb-20-20 08:00AM	Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer GlobeNewswire +6.32%
Feb-05-20 04:11PM	13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market Benzinga
Feb-04-20 08:04AM	Are Insiders Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock? Simply Wall St.
08:00AM	Galectin Therapeutics President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020 GlobeNewswire
Dec-20-19 06:38PM	Is Galectin Therapeutics Inc. (GALT) Going to Burn These Hedge Funds? Insider Monkey
Dec-09-19 08:00AM	Galectin Therapeutics Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology GlobeNewswire
Dec-05-19 12:06PM	Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis GlobeNewswire
Nov-26-19 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders GlobeNewswire
Nov-18-19 04:10PM	Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit GlobeNewswire
Nov-12-19 08:00AM	Galectin Therapeutics Reports Q3 2019 Financial Results GlobeNewswire -16.90%
Nov-11-19 09:47AM	Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis GlobeNewswire +8.82%
Nov-05-19 08:00AM	Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting GlobeNewswire
Oct-28-19 08:39AM	We're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash Burn Simply Wall St.
Sep-17-19 08:00AM	Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy GlobeNewswire
Sep-11-19 10:13AM	Small Drug Stock Outlook: Innovation Holds the Key to Growth Zacks +5.57%
Aug-27-19 03:21PM	Need To Know: Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Have Been Buying Shares Simply Wall St. -5.66%
10:21AM	New Strong Buy Stocks for August 27th Zacks
09:00AM	FibroGen (FGEN) Catches Eye: Stock Jumps 7.4% Zacks
Aug-09-19 08:00AM	Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-07-19 11:20AM	Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View Zacks
11:15AM	Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y Zacks
Aug-06-19 10:51AM	Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance Zacks
Aug-05-19 08:05AM	Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA GlobeNewswire
May-28-19 09:05AM	Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise GlobeNewswire
May-27-19 08:44AM	What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)? Simply Wall St.
May-23-19 05:30PM	Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering GlobeNewswire
May-10-19 08:05AM	Galectin Therapeutics Releases Richard E. Uihleins Open Letter to Stockholders Dated May 10, 2019 GlobeNewswire
08:00AM	Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-15-19 08:00AM	Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement GlobeNewswire
Apr-02-19 08:00AM	Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-22-19 10:19AM	Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology GlobeNewswire
Mar-06-19 11:34AM	Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248% Simply Wall St.
08:03AM	Galectin Therapeutics Releases Richard E. Uihleins Open Letter to Stockholders GlobeNewswire
08:02AM	Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants GlobeNewswire
08:00AM	Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update GlobeNewswire
Feb-26-19 07:25AM	Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-25-19 08:00AM	Galectin Therapeutics to Present at Berenberg NASH Day in New York GlobeNewswire
Feb-13-19 03:36PM	Conatus (CNAT) Completes Enrollment in Phase II NASH Study Zacks
09:53AM	Ascendis Pharma Files IND for Hypoparathyroidism Candidate Zacks
Feb-04-19 09:27AM	Alkermes Sinks as FDA Refuses to Approve Depression Drug Zacks
Feb-01-19 10:07AM	AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA Zacks

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FREEMAN KEVIN D	Director	Apr 18	Buy	1.71	5,000	8,550	60,000	Apr 18 03:59 PM
Zordani Richard A. Jr.	Director	Apr 04	Buy	1.60	5,000	8,025	24,583	Apr 04 02:58 PM
10X Fund, L.P.	10% Owner	Feb 02	Sale	2.10	10,000	21,000	6,178,940	Feb 04 06:23 PM
Schwartz Elissa J.	Director	Jan 21	Buy	2.00	1,000	2,000	1,000	Jan 24 08:42 AM
FREEMAN KEVIN D	Director	Jan 19	Buy	1.96	5,000	9,806	50,000	Jan 19 11:02 AM
Zordani Richard A. Jr.	Director	Jan 14	Buy	2.02	5,000	10,100	19,583	Jan 18 08:54 AM
10X Fund, L.P.	10% Owner	Jan 11	Sale	2.10	10,000	21,000	6,188,940	Jan 13 03:42 PM
FREEMAN KEVIN D	Director	Dec 06	Buy	2.28	5,000	11,400	50,000	Dec 15 04:25 PM
FREEMAN KEVIN D	Director	Dec 06	Buy	2.34	5,000	11,700	45,000	Dec 06 02:09 PM
10X Fund, L.P.	10% Owner	Dec 02	Sale	2.37	10,000	23,700	6,198,940	Dec 06 12:42 PM
10X Fund, L.P.	10% Owner	Nov 01	Sale	3.19	10,000	31,900	6,208,940	Nov 04 11:55 AM
FREEMAN KEVIN D	Director	Oct 29	Buy	3.17	2,000	6,340	40,000	Nov 01 12:51 PM
FREEMAN KEVIN D	Director	Oct 21	Buy	3.19	2,000	6,380	38,000	Oct 21 12:52 PM
FREEMAN KEVIN D	Director	Oct 19	Buy	3.37	3,000	10,107	36,000	Oct 19 02:14 PM
10X Fund, L.P.	10% Owner	Oct 15	Sale	3.37	10,000	33,700	6,218,940	Oct 19 03:18 PM
10X Fund, L.P.	10% Owner	Oct 04	Sale	3.62	10,000	36,200	6,228,940	Oct 06 12:00 PM
FREEMAN KEVIN D	Director	Sep 23	Buy	3.88	3,000	11,631	33,000	Sep 23 04:14 PM
10X Fund, L.P.	10% Owner	Sep 01	Sale	3.91	10,000	39,100	6,238,940	Sep 03 09:00 AM
10X Fund, L.P.	10% Owner	Aug 02	Sale	3.25	10,000	32,500	6,248,940	Aug 03 03:48 PM
10X Fund, L.P.	10% Owner	Jul 09	Sale	3.54	10,000	35,400	6,258,940	Jul 15 02:27 PM
10X Fund, L.P.	10% Owner	Jun 01	Sale	3.91	10,000	39,100	6,268,940	Jun 03 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience